Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
Sagimet Biosciences (Nasdaq: SGMT) announced three presentations at the AASLD - The Liver Meeting® 2024 in San Diego, showcasing data on their fatty acid synthase (FASN) inhibitor, denifanstat. The presentations include:
1. An oral presentation on AI-based digital pathology results from the FASCINATE-2 study, demonstrating denifanstat's improvement of fibrosis parameters and reduction of progression to cirrhosis in MASH patients.
2. A poster on denifanstat's reduction of atherosclerosis development in a mouse model of dyslipidaemia and MASH, suggesting potential cardiovascular and liver health benefits.
3. A poster highlighting denifanstat's significant improvement of liver fibrosis in difficult-to-treat MASH patients, based on conventional and AI-based pathology from the Phase 2b FASCINATE-2 trial.
These presentations underscore denifanstat's potential as a novel therapeutic for metabolic and fibrotic pathways in liver disease.
Sagimet Biosciences (Nasdaq: SGMT) ha annunciato tre presentazioni all'AASLD - The Liver Meeting® 2024 di San Diego, dove ha mostrato dati sul loro inibitore della sintesi degli acidi grassi (FASN), denifanstat. Le presentazioni includono:
1. Una presentazione orale sui risultati della patologia digitale basata su AI dello studio FASCINATE-2, che dimostra il miglioramento dei parametri di fibrosi e la riduzione della progressione verso la cirrosi nei pazienti con MASH.
2. Un poster sulla riduzione dello sviluppo dell'aterosclerosi in un modello murino di dislipidemia e MASH con denifanstat, suggerendo potenziali benefici per la salute cardiovascolare e epatica.
3. Un poster che evidenzia il significativo miglioramento della fibrosi epatica in pazienti con MASH difficili da trattare, basato su patologie convenzionali e su AI dallo studio clinico di Fase 2b FASCINATE-2.
Queste presentazioni sottolineano il potenziale di denifanstat come una nuova terapia per i percorsi metabolici e fibrotici nelle malattie epatiche.
Sagimet Biosciences (Nasdaq: SGMT) anunció tres presentaciones en el AASLD - The Liver Meeting® 2024 en San Diego, exhibiendo datos sobre su inhibidor de la sintasa de ácidos grasos (FASN), denifanstat. Las presentaciones incluyen:
1. Una presentación oral sobre resultados de patología digital basada en IA del estudio FASCINATE-2, que demuestra la mejora de los parámetros de fibrosis y la reducción de la progresión a cirrosis en pacientes con MASH.
2. Un póster sobre la reducción del desarrollo de aterosclerosis en un modelo de ratón de dislipidemia y MASH con denifanstat, sugiriendo beneficios potenciales para la salud cardiovascular y hepática.
3. Un póster que destaca la mejora significativa de la fibrosis hepática en pacientes con MASH difíciles de tratar, basado en patologías convencionales y en IA del ensayo de fase 2b FASCINATE-2.
Estas presentaciones resaltan el potencial de denifanstat como una terapia innovadora para las vías metabólicas y fibróticas en enfermedades hepáticas.
사기멧 바이오사이언스 (Nasdaq: SGMT)는 샌디에이고에서 열리는 AASLD - The Liver Meeting® 2024에서 지방산 합성 효소(FASN) 억제제인 데니판스타트에 대한 세 가지 발표를 발표했습니다. 발표 내용은 다음과 같습니다:
1. FASCINATE-2 연구의 AI 기반 디지털 병리학 결과에 대한 구두 발표로, MASH 환자에서 데니판스타트가 섬유증 매개변수를 개선하고 간경변으로의 진행을 줄이는 것을 시연했습니다.
2. 디슬리피데미아 및 MASH 쥐 모델에서의 데니판스타트의 동맥경화증 발병 감소에 대한 포스터로, 심혈관 및 간 건강에 대한 잠재적 이점을 제시합니다.
3. 2상 FASCINATE-2 시험에서 전통적인 및 AI 기반 병리학에 근거한 치료하기 어려운 MASH 환자에서 간 섬유증의 유의미한 개선을 보여주는 포스터입니다.
이 발표들은 간 질환의 대사 및 섬유증 경로에 대한 새로운 치료법으로서 데니판스타트의 잠재력을 강조합니다.
Sagimet Biosciences (Nasdaq: SGMT) a annoncé trois présentations lors de la AASLD - The Liver Meeting® 2024 à San Diego, présentant des données sur leur inhibiteur de la synthèse des acides gras (FASN), denifanstat. Les présentations incluent :
1. Une présentation orale sur les résultats de pathologie numérique basée sur l'IA de l'étude FASCINATE-2, démontrant l'amélioration des paramètres de fibrose et la réduction de la progression vers la cirrhose chez les patients MASH.
2. Un poster sur la réduction du développement de l'athérosclérose dans un modèle murin de dyslipidémie et MASH, suggérant des avantages potentiels pour la santé cardiovasculaire et hépatique.
3. Un poster soulignant l'amélioration significative de la fibrose hépatique chez les patients MASH difficiles à traiter, basé sur la pathologie conventionnelle et basée sur l'IA de l'essai de Phase 2b FASCINATE-2.
Ces présentations soulignent le potentiel de denifanstat en tant que nouvelle thérapie pour les voies métaboliques et fibrosées dans les maladies hépatiques.
Sagimet Biosciences (Nasdaq: SGMT) hat drei Präsentationen auf dem AASLD - The Liver Meeting® 2024 in San Diego angekündigt, in denen Daten zu ihrem Fettsäuresynthase (FASN) Inhibitor denifanstat vorgestellt werden. Die Präsentationen umfassen:
1. Eine mündliche Präsentation zu AI-gestützten digitalen Pathologieergebnissen aus der FASCINATE-2 Studie, die die Verbesserung der Fibroseparameter und die Verringerung der Progression zur Zirrhose bei MASH-Patienten zeigt.
2. Ein Poster über die Reduzierung der Atheroskleroseentwicklung in einem Mausmodell für Dyslipidämie und MASH, was auf potenzielle Vorteile für die kardiovaskuläre Gesundheit und Lebergesundheit hinweist.
3. Ein Poster, das die signifikante Verbesserung der Leberfibrose bei schwer zu behandelnden MASH-Patienten hervorhebt, basierend auf konventioneller und AI-basierter Pathologie aus der Phase-2b-Studie FASCINATE-2.
Diese Präsentationen unterstreichen das Potenzial von denifanstat als neuartige Therapie für metabolische und fibrotische Wege bei Lebererkrankungen.
- None.
- None.
SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor, denifanstat, and preclinical data demonstrating atherosclerosis improvement with FASN inhibitor treatment, will be highlighted in three presentations at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2024, taking place November 15-19, 2024 in San Diego, California.
Details of accepted abstracts can be found below:
Oral Presentation:
| Title: | AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis – results of the FASCINATE-2 study |
| Session: | MASLD and MASH - New Therapies |
| Date/Time: | Sunday, November 17 at 2:45pm PT |
| Location: | San Diego Convention Center, Poster Hall |
| Presenting author: | Mary Rinella, M.D., University of Chicago |
Denifanstat, an oral FASN inhibitor, demonstrated statistically significant MASH resolution and fibrosis improvement and decreased liver fat and biomarkers of inflammation and fibrosis in the Phase 2b study FASCINATE-2. AI digital pathology results confirm denifanstat’s reduction of liver fibrosis and steatosis in MASH shown in the FASCINATE-2 study.
Poster Presentations:
| Title: | Fatty acid synthase (FASN) inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH |
| Session: | MASLD/MASH - Experimental: Basic |
| Date: | Friday, November 15 |
| Location: | San Diego Convention Center, Poster Hall |
| Presenting author: | Wen-Wei Tsai, Ph.D., Sagimet Biosciences |
In a mouse model of dyslipidaemia and MASH, FASN inhibition by denifanstat not only reduced circulating cholesterol, but also decreased the development of atherosclerosis and improved liver histology. These results suggest that denifanstat, once approved, could potentially offer benefits in both cardiovascular and liver health benefits to patients and support its future clinical evaluation for long term outcomes in MASH patients.
| Title: | Denifanstat significantly improves liver fibrosis in difficult-to-treat metabolic dysfunction-associated steatohepatitis (MASH) patients. Results from conventional and AI-based pathology from the Phase 2b FASCINATE-2, a 52-week randomized, double blind, placebo-controlled trial of fatty acid synthase (FASN) inhibitor denifanstat, in F2/F3 MASH |
| Session: | MASLD/MASH - Therapeutics: New Agents |
| Date: | Sunday, November 17 |
| Location: Presenting author: | San Diego Convention Center, Poster Hall Rohit Loomba, M.D., M.H.Sc., University of California San Diego |
Denifanstat’s impact on fibrosis in the overall Phase 2b study population as well as in difficult-to-treat subsets was evaluated by conventional histopathology and second harmonic generation AI-based digital pathology. Denifanstat demonstrated statistically significant improvement in liver fibrosis without worsening of MASH, including 2-stage fibrosis improvement in difficult-to-treat MASH.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH. FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. For additional information about Sagimet, please visit www.sagimet.com.
About MASH
MASH is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and diagnosis.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines, including its Phase 3 denifanstat program; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
What is Sagimet Biosciences presenting at AASLD - The Liver Meeting® 2024?
What are the key findings from the FASCINATE-2 study on denifanstat?
How did denifanstat affect atherosclerosis in preclinical studies?
What results did AI-based digital pathology show for denifanstat in MASH patients?
When and where will Sagimet Biosciences (SGMT) present their findings on denifanstat?
